A Cross-sectional Survey of Physicians to Understand Biomarker Testing and Treatment Patterns in Patients with Prostate Cancer in the USA, EU5, Japan, and China.

ABSTRACT:

Background and objective

Treatment landscape in advanced prostate cancer (PC) is evolving. There is limited understanding of the factors influencing decision-making for genetic/genomic testing and the barriers to recommending testing and treatment in international real-world clinical practice following the approval of poly-adenosine diphosphate-ribose polymerase inhibitors (PARPi) for metastatic castration-resistant PC (mCRPC). This work aims to assess genetic/genomic testing patterns and methods, including for homologous recombination repair mutation (HRRm), and treatment decisions among physicians caring for patients with PC across the USA, Europe, and Asia.

Methods

A cross-sectional online survey of physicians treating patients with advanced PC was administered in the USA

SUBMITTER: Gratzke C 

PROVIDER: S-EPMC11751505 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature